Abiopharma

News list

AXSOME THERAPEUTICS, INC. (AXSM)

SEC News
May 04, 2026, 11:07 UTC

(30% Negative) AXSOME THERAPEUTICS, INC. (AXSM) Reports Q2 2026 Financial Results

Full text

News bot May 4, 2026, 11:08 a.m.

📋 AXSOME THERAPEUTICS, INC. (AXSM) - Financial Results

Filing Date: 2026-05-04

Accepted: 2026-05-04 07:07:33

Event Type: Financial Results

Event Details:

AXSOME THERAPEUTICS, INC. (AXSM) Reports the reporting period Financial Results AXSOME THERAPEUTICS, INC. (AXSM) announced its financial results for the period ending the reporting period. Key Financial Highlights:

Revenue: 14725
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: 305106
- anticipated in 2026
- targeting ten conditions with significant unmet medical need in psychiatry and neurology, Axsome is positioned to advance the frontiers of brain health for patients, and deliver substantial value for shareholders.”First Quarter 2026

📊 Key Financial Metrics (Year-over-Year Comparison):

Metric	2026	2025	Change ($)	Change (%)
Current Assets Intangible Assets Net	38.95K	40.52K	$-1.57K	-3.88%
Current Liabilities Accounts Payable	106.70K	65.54K	$41.16K	+62.81%
Operating Expenses Selling General Administrative	185.00K	120.79K	$64.21K	+53.16%
Operating Expenses Loss From Operations	63.36K	56.98K	$6.38K	+11.19%
Operating Expenses Interest Expense	1.19K	2.43K	$-1.25K	-51.25%
Income Tax Expense Net Loss	64.54K	59.41K	$5.13K	+8.63%
Income Tax Expense Net Loss Per Share	1.26	1.22	$0.04	+3.28%
Other Assets	30.83K	26.84K	$3.99K	+14.88%
Accounts Payable	106.70K	65.54K	$41.16K	+62.81%
Revenue	1.80K	1.10K	$698.00	+63.17%
Selling, General & Administrative	185.00K	120.79K	$64.21K	+53.16%
Loss from Operations	63.36K	56.98K	$6.38K	+11.19%
Interest Expense	1.19K	2.43K	$-1.25K	-51.25%
Net Loss	64.54K	59.41K	$5.13K	+8.63%

💼 Business Developments:

Partnership
Acquisition
Licensing
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: AXSOME THERAPEUTICS, INC.
Ticker Symbol: AXSM